The wound healing platform generates a first commercial partnership for Advitech.


    TSX VENTURE EXCHANGE: AVI

    QUEBEC CITY, Dec. 6 /CNW Telbec/ - Following the October 10, 2007
announcement made by Advitech ("Advitech" or the "Corporation") (TSX Venture
Exchange: AVI) on positive pre-clinical results for wound healing
applications, the Corporation announces today the signature of a letter of
intent with Dectro International for the sale and marketing of a complete
microdermabrasion product line. A definitive agreement must be finalized by
December 31, 2007.
    The IM product line, which will comprise specific dairy bioactives,
generated from the XP-828L technological platform, will be a unique approach
combining systemic and topical products aiming for an accelerated recovery
process following a microdermabrasion procedure. The product line is a result
of the Corporation's ongoing work on both a new platform in development, and
its main technological platform, XP-828L. The line will include three
products: IMO-137 (oral) will be used throughout a preparation phase and after
treatment, IMS-137 (topical serum) will be used immediately after the
procedure and IMC-137 (cream) will be used at home by the customer to assist
in the healing process.
    "We are proud of this upcoming partnership with Dectro since that will
allow us to commercialize a line of unique products in 2008. We have made
exceptional progress, in the past few months, with this new application and
expect to rapidly generate additional revenue. Dectro is a world leader in
microdermabrasion and together we hope to build a strong portfolio of products
around Dectro's Gala brand name" commented Renaud Beauchesne, Advitech's
President and Chief Executive Officer. "The association Advitech-Dectro will
enable us to offer a unique concept of products and solidify our leadership
position", added Mr. Clément Beaumont, President and General Manager of Dectro
International.
    The IM product line will be included in the Gala cosmetics line developed
and sold exclusively by Dectro in estheticians clinics.

    About Dectro International: www.dectro.com

    For more than 20 years, Dectro International has developed and
commercialized specialized devices and cosmetic products for the esthetical
care market. Dectro is a world leader in microdermabrasion performed in
esthetic clinics. It manages a network of exclusive distributors in all major
countries. In North America, Dectro operates three distribution centers (in
Quebec and California) serving more than 7,000 clinics.

    About microdermabrasion:

    Microdermabrasion is a cosmetic or medical procedure in which the surface
of the epidermis of the skin is removed by abrasion. It is used to remove
sun-damaged skin and to reduce certain scars and wrinkles.

    About Advitech Inc. www.advitech.com

    Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Advitech is also active in the development of wound healing
applications. Recently, Advitech launched Dermylex(TM) for the treatment of
mild-to-moderate psoriasis. The Corporation has drawn up a research program to
develop new applications related to Wound Healing. This development is derived
from both its XP-828L technological platform and a new colostrums platform .

    This press release contains forward-looking statements which reflect the
Corporation's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual results
could differ materially from those projected herein. The TSX Venture Exchange
does not accept responsibility for the adequacy or accuracy of this release.
    %SEDAR: 00021006EF



For further information: Advitech Inc.: Renaud Beauchesne, MBA,
President and Chief Executive Officer, (418) 686-7498, ext. 228,
info@advitech.com, www.advitech.com; Serge Comeau, Investor's relations, (514)
862-4160, s.comeau@advitech.com